148
Journals
668.9K
Articles
12.3M
Citations
108.5K
Authors

Most Cited Articles of Hematology in 2022

TitleJournalYearCitations
Cancer statistics, 2022.Ca-A Cancer Journal for Clinicians2022842
Cancer statistics for African American/Black People 2022.Ca-A Cancer Journal for Clinicians202217
Cancer vaccines as promising immuno-therapeutics: platforms and current progress.Journal of Hematology and Oncology202216
Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.Annals of Oncology202215
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia.Leukemia202215
MOLECULAR CHARACTERIZATION OF MUTANT TP53 ACUTE MYELOID LEUKEMIA AND HIGH-RISK MYELODYSPLASTIC SYNDROME.Blood202214
The long and short non-coding RNAs modulating EZH2 signaling in cancer.Journal of Hematology and Oncology202212
Multiple Myeloma: 2022 update on Diagnosis, Risk-stratification and Management.American Journal of Hematology202212
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIP Michelangelo randomized study.Annals of Oncology202211
Resuscitation with blood products in patients with trauma-related haemorrhagic shock receiving prehospital care (RePHILL): a multicentre, open-label, randomised, controlled, phase 3 trial.Lancet Haematology,the202211
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase 3 trial.Annals of Oncology202210
Vasculopathy in COVID-19.Blood202210
CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity.Blood Cancer Discovery202210
First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.Annals of Oncology202210
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.Blood202210
VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 studyAnnals of Oncology202210
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase 3 iLLUMINATE trial.Haematologica20229
Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer.Annals of Oncology20229
Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.Lancet Haematology,the20229
The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline.Annals of Oncology20229
Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies.Journal of Hematology and Oncology20229
European cancer mortality predictions for the year 2022 with focus on ovarian cancer.Annals of Oncology20228
TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML.Blood Advances20228
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.Journal of Hematology and Oncology20228
Clinical management of metastatic colorectal cancer in the era of precision medicine.Ca-A Cancer Journal for Clinicians20228